Citadel Advisors’s PharmaCyte Biotech PMCB Stock Holding History

Citadel Advisors’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$218K	Sell	283,381 -76,166	-21%	-$57.3K	﹤0.01%	11867
2026 Q1	$239K	Buy	359,547 +129,825	+57%	+$99.3K	﹤0.01%	11015
2025 Q4	$166K	Buy	229,722 +215,191	+1,481%	+$194K	﹤0.01%	11205
2025 Q3	$14.1K	Buy	+14,531	New	+$14.5K	﹤0.01%	12539
2024 Q2	–	Sell	-8,561	Closed	-$20.3K	–	15122
2024 Q1	$20.3K	Sell	8,561 -20,057	-70%	-$43.4K	﹤0.01%	13009
2023 Q4	$61.8K	Sell	28,618 -6,766	-19%	-$14.7K	﹤0.01%	11561
2023 Q3	$74.3K	Sell	35,384 -29,524	-45%	-$75.3K	﹤0.01%	11257
2023 Q2	$186K	Sell	64,908 -11,103	-15%	-$33.3K	﹤0.01%	10006
2023 Q1	$221K	Buy	76,011 +58,508	+334%	+$172K	﹤0.01%	10005
2022 Q4	$51.1K	Buy	+17,503	New	+$50.1K	﹤0.01%	12109
2022 Q3	–	Sell	-31,696	Closed	-$80.2K	–	13361
2022 Q2	$72K	Buy	+31,696	New	+$69.3K	﹤0.01%	11687

Other funds holding PMCB

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

EPM

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Citadel Advisors's PMCB Position: Q2 2026 in Review

Citadel Advisors reduced its PharmaCyte Biotech (PMCB) stake by 21% in Q2 2026, selling an estimated $57.3K and leaving 283,381 shares worth $218K. The position accounts for ﹤0.01% of the portfolio, ranked #11867.

Citadel Advisors first reported a position in PMCB in Q2 2022 and has held it in 11 quarters since. The position peaked at $239K in Q1 2026. 28 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

Citadel Advisors held 283,381 shares of PharmaCyte Biotech worth $218K as of Q2 2026.
Citadel Advisors sold 76,166 PharmaCyte Biotech shares in Q2 2026, an estimated $57.3K.
PharmaCyte Biotech made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #11867 holding.
Citadel Advisors first reported a position in PharmaCyte Biotech in Q2 2022 and has held it in 11 quarters since.
Citadel Advisors's PharmaCyte Biotech position peaked at $239K in Q1 2026.
28 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.